Methods of treating mild brain injury

A method of reducing the incidence of or severity of mild brain injury (mBI) in a subject in need thereof, comprising administering to the subject an effective amount of a ghrelin variant, thereby reducing the incidence or severity of the mBI.

A method of reducing the amount of time needed to recover from a mild brain injury (mBI), comprising administering to a patient suffering from a mild brain injury a therapeutically effective amount of a ghrelin variant within 72 hours of the mBI.

A therapeutic product comprising a at least two agents selected from the group consisting of ghrelin, a ghrelin variant, an anti-inflammatory agent, anti-pain medication, acetylsalicylic acid, an antiplatelet agent, a thrombolytic enzyme, an aggregation inhibitor, a glycoprotein IIb/IIIa inhibitor, a glycosaminoglycan, a thrombin inhibitor, an anticoagulant, heparin, coumarin, tPA, GCSF, streptokinase, urokinase, Ancrod, melatonin, a caspase inhibitor, an NMDA receptor agonist or antagonist, an anti-TNF-α compound, an antibody, erythropoietin/EPO, angiotensin II lowering agent, selective androgen receptor modulator, leptin or leptin mimetics and variants, an agonists of the renin-angiotensin system, an opioid receptor agonist, progesterone or progesterone mimetics and variants, a peroxisome proliferator-activated receptor gamma agonist, an NMDA receptor agonist or antagonist (e.g. OTO-311), P2Y purinergic receptor agonists (e.g., 2-MeSADP, MRS2365), P7C3, aducanumab, and amantadine (e.g. ADS-5102).

The therapeutic product of 56, further comprising a pharmaceutically acceptable excipient.

The therapeutic product of 57, wherein the pharmaceutically acceptable excipient comprises saline.

A method of treating mild brain injury (mBI) or concussion in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of ghrelin or ghrelin variant in an amount that provides blood levels of ghrelin that are at least 1.5 times greater than endogenous ghrelin blood levels of the subject, thereby treating the mBI or concussion.

A method for detecting and treating mild brain injury or concussion in a subject in need thereof, comprising measuring the amount of biomarkers in a sample of the subject after the occurrence of a mild brain injury or concussion;

• comparing the amount of the biomarkers in the sample with a sample from an uninjured subject;
• and administering to the subject a therapeutically effective amount of a composition comprising ghrelin and/or ghrelin variant.